In the past 12–18 months the Neonatal Respiratory Distress Syndrome Treatment industry trends have been reshaped by several high‑impact moves. Philips Healthcare entered a strategic partnership with Medtronic to co‑develop an integrated surfactant delivery platform that combines real‑time lung imaging with automated dosing. In Q2 2024, Roche completed the acquisition of PulmoGenix, adding a pipeline of synthetic surfactants to its respiratory portfolio. Insmed launched the first nebulized surfactant device, SurfaNeb™, which received FDA clearance in March 2024 and is expected to broaden outpatient care. The European Medicines Agency revised its guidance on neonatal surfactant trials, shortening approval timelines and encouraging adaptive study designs. A noticeable shift toward home‑based NICU monitoring has emerged, driven by tele‑health reimbursement expansions in the U.S. and Europe. Meanwhile, NeoVentix, a Boston‑based startup, secured $85 million in Series B funding to scale its AI‑driven ventilation analytics platform, and announced a new manufacturing hub in Singapore to meet rising Asian demand. These developments collectively point to a more collaborative, technology‑focused, and globally diversified market landscape.